| dc.contributor.author | Ethiopian Food and Drug Authority | |
| dc.date.accessioned | 2026-02-24T06:49:53Z | |
| dc.date.available | 2026-02-24T06:49:53Z | |
| dc.date.issued | 2023 | |
| dc.identifier.uri | http://repository.iphce.org/xmlui/handle/123456789/5321 | |
| dc.description.abstract | As part of the global recommendation, the national TB program and Ethiopian Food and Drug Authority have set active TB-drugs safety monitoring and management (aDSM) as an essential requirement during the introduction of new anti-TB drugs and regimens. Hence, proper implementation of aDSM is evaluated by the presence of effective monitoring, detection, management, recording, and reporting of adverse drug events of MDR-TB drugs. | en_US |
| dc.language.iso | en_US | en_US |
| dc.subject | anti-TB drugs | en_US |
| dc.title | Adverse drug reactions related to drug-resistant tuberculosis (DR-TB) treatment in Ethiopia: Active tuberculosis drug-safety monitoring and management | en_US |
| dc.type | Report | en_US |